Glitazones in chronic kidney disease: Potential and concerns

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 3, 2012, Pages 167-175

  Bolignano, D ^a   Zoccali, C ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Albuminuria; Cardiovascular outcomes; Chronic kidney disease; Glitazones; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DIABETIC NEPHROPATHY; EVIDENCE BASED MEDICINE; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84857861796     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.11.005     Document Type: Review

References (60)

1. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. Global burden of metabolic risk factors of chronic diseases collaborating group (blood glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011, 378:31-40.
2. U.S.Department of Health and Human Services, Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, Available at:, [accessed 05.10.11]. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
3. Fox C.S., Pencina M.J., Meigs J.B., Vasan R.S., Levitzky Y.S., D'Agostino R.B. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham heart study. Circulation 2006, 113:2914.
4. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106.
5. Uwaifo G.I., Ratner R.E. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007, 99:51B.
6. Wajcberg E., Sriwijitkamol A., Musi N., DeFronzo R.A., Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab 2007, 92:1256.
7. Nicholls S.J., Tuzcu E.M., Wolski K., Bayturan O., Lavoie A., Uno K., et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone effect on regression of intravascular sonographic coronary obstruction prospective evaluation) study. J Am Coll Cardiol 2011, 57:153-159.
8. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572.
9. Stocker D.J., Taylor A.J., Langley R.W., Jezior M.R., Vigersky R.A. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007, 153:445.
10. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457.
11. Lipscombe L.L., Gomes T., Lévesque L.E., Hux J.E., Juurlink D.N., Alter D.A. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634.
12. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411.
13. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125.
14. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180.
15. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005, 366:1279.
16. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007, 49:1772.
17. Chiquette E., Ramirez G., Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164:2097.
18. Kaul S., Bolger A.F., Herrington D., Giugliano R.P., Eckel R.H. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010, 121:1868.
19. United States Renal Data System; 2011 Annual Data Report available at: [accessed 05.10.11]. http://www.usrds.org/adr.aspx.
20. Zoccali C., Kramer A., Jager K. The databases: renal replacement therapy since 1989-the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). Clin J Am Soc Nephrol 2009, 4(Suppl 1):S18-S22.
21. Schneider C.A., Ferrannini E., Defronzo R., Schernthaner G., Yates J., Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008, 19:182-187.
22. Brunelli S.M., Thadhani R., Ikizler T.A., Feldman H.I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009, 75:961-968.
23. Ramirez S.P., Albert J.M., Blayney M.J., Tentori F., Goodkin D.A., Wolfe R.A., et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009, 20:1094-1101.
24. Gansevoort R.T., Nauta F.L., Bakker S.J. Albuminuria: all you need to predict outcomes in chronic kidney disease?. Curr Opin Nephrol Hypertens 2010, 19:513-518.
25. De Cosmo S., Motterlini N., Prudente S., Pellegrini F., Trevisan R., Bossi A., BENEDICT study group, et al. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009, 58:2920-2929.
26. Guan Y., Zhang Y., Schneider A., Davis L., Breyer R.M., Breyer M.D. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Ren Physiol 2001, 281:F1036-F1046.
27. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., et al. Upregulation of type 1 collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Ren Physiol 2002, 282:F639-F648.
28. Fogo A.B. PPARγ and chronic kidney disease. Pediatr Nephrol 2011, 26:347-351.
29. Nicholas S.B., Kawano Y., Wakino S., Collins A.R., Hsueh W.A. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001, 37:722-727.
30. Dong F.Q., Li H., Cai W.M., Tao J., Li Q., Ruan Y., et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (England) 2004, 117:1040-1044.
31. Nakamura T., Ushiyama C., Shimada N., Hayashi K., Ebihara I., Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complicat 2000, 14:250-254.
32. Higashi K., Oda T., Kushiyama T., Hyodo T., Yamada M., Suzuki S., et al. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton) 2010, 15:327-335.
33. Arima S., Kohagura K., Takeuchi K., Taniyama Y., Sugawara A., Ikeda Y., et al. Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol 2002, 13:342-349.
34. Kashihara N., Haruna Y., Kondeti V.K., Kanwar Y.S. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010, 17:4256-4269.
35. Yang J., Zhang D., Li J., Zhang X., Fan F., Guan Y. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clin Sci (Lond) 2009, 116:17-26.
36. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003, 74:553-562.
37. Dai B., Liu Y., Mei C., Fu L., Xiong X., Zhang Y., et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 2010, 119:323-333.
38. Imano E., Kanda T., Nakatani Y., Nishida T., Arai K., Motomura M., et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998, 21:2135-2139.
39. Nakamura T., Ushiyama C., Suzuki S., Shimada N., Sekizuka K., Ebihara L., et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001, 18:308-313.
40. Hanefeld M., Brunetti P., Schernthaner G.H., Matthews D.R., Charbonnel B.H., QUARTET study group One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27:141-147.
41. Matthews D.R., Charbonnel B.H., Hanefeld M., Brunetti P., Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005, 21:167-174.
42. Yanagawa T., Araki A., Sasamoto K., Shirabe S., Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004, 53:353-357.
43. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I., Rosiglitazone Clinical Trials Study Group Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
44. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17:7-12.
45. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54:2206-2211.
46. Bakris G.L., Ruilope L.M., McMorn S.O., Weston W.M., Heise M.A., Freed M.I., et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006, 24:2047-2055.
47. Davidson J.A., McMorn S.O., Waterhouse B.R., Cobitz A.R. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther 2007, 29:1900-1914.
48. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-847.
49. Kim M.K., Ko S.H., Baek K.H., Ahn Y.B., Yoon K.H., Kang M.I., et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 2009, 24:227-232.
50. Peyser A., Machardy N., Tarapore F., Machardy J., Powell L., Gipson D.S., et al. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol 2010, 11:2.
51. Aljabri K., Kozak S.E., Thompson D.M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004, 116:230-235.
52. Sironi A.M., Vichi S., Gastaldelli A., Pecori N., Anichini R., Foot E., et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997, 62:194-202.
53. Agarwal R., Saha C., Battiwala M., Vasavada N., Curley T., Chase S.D., et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005, 68:285-292.
54. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Hitoglou-Makedou A.D., Pagkalos E.M., Yovos J.G., et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005, 18:227-234.
55. Tobe S.W., Clase C.M., Gao P., McQueen M., Grosshennig A., Wang X., ONTARGET and TRANSCEND Investigators, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123:1098-1107.
56. Berria R., Glass L., Mahankali A., Miyazaki Y., Monroy A., De Filippis E., et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007, 82:275-281.
57. Abe M., Okada K., Maruyama T., Maruyama N., Soma M., Matsumoto K. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010, 11:1611-1620.
58. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
59. Bilik D., McEwen L.N., Brown M.B., Pomeroy N.E., Kim C., Asao K., et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010, 95:4560.
60. Meier C., Kraenzlin M.E., Bodmer M., Jick S.S., Jick H., Meier C.R. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820.